Kite Pharma Inc. (NASDAQ:KITE) shares traded up 4.5% on Monday . The stock traded as high as $63.10 and last traded at $62.87, with a volume of 592,233 shares changing hands. The stock had previously closed at $60.16.

Several research analysts recently weighed in on the company. Vetr cut Kite Pharma from a “hold” rating to a “sell” rating and set a $57.97 price target for the company. in a research report on Monday. Mizuho set a $80.00 price objective on Kite Pharma and gave the company a “buy” rating in a report on Tuesday, August 9th. Barclays PLC set a $60.00 price objective on Kite Pharma and gave the company a “hold” rating in a report on Tuesday, August 9th. Maxim Group reissued a “buy” rating and issued a $77.00 price objective (down from $87.00) on shares of Kite Pharma in a report on Tuesday, August 9th. Finally, Jefferies Group reissued a “buy” rating on shares of Kite Pharma in a report on Friday, August 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company. Kite Pharma has an average rating of “Buy” and an average target price of $73.53.

The company’s 50 day moving average price is $53.42 and its 200-day moving average price is $49.30. The firm’s market cap is $3.07 billion.

Kite Pharma (NASDAQ:KITE) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.21) by $0.30. During the same period last year, the company posted ($0.26) earnings per share. The business had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $4.86 million. The business’s quarterly revenue was up 9.1% on a year-over-year basis. Analysts expect that Kite Pharma Inc. will post ($5.83) EPS for the current fiscal year.

In other news, SVP Jeffrey Wiezorek sold 1,500 shares of the stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $50.00, for a total transaction of $75,000.00. Following the completion of the transaction, the senior vice president now directly owns 16,367 shares of the company’s stock, valued at approximately $818,350. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Roy Doumani sold 10,000 shares of the stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $57.91, for a total value of $579,100.00. Following the transaction, the director now directly owns 136,017 shares of the company’s stock, valued at $7,876,744.47. The disclosure for this sale can be found here.

A number of institutional investors have recently added to or reduced their stakes in the stock. Mutual of America Capital Management LLC increased its position in Kite Pharma by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 16,336 shares of the biopharmaceutical company’s stock valued at $1,007,000 after buying an additional 95 shares during the last quarter. Morgan Stanley increased its position in Kite Pharma by 3.5% in the fourth quarter. Morgan Stanley now owns 21,628 shares of the biopharmaceutical company’s stock valued at $1,332,000 after buying an additional 739 shares during the last quarter. Rhumbline Advisers increased its position in Kite Pharma by 10.2% in the fourth quarter. Rhumbline Advisers now owns 28,768 shares of the biopharmaceutical company’s stock valued at $1,773,000 after buying an additional 2,660 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in Kite Pharma during the fourth quarter valued at $2,088,000. Finally, California Public Employees Retirement System increased its position in Kite Pharma by 58.8% in the fourth quarter. California Public Employees Retirement System now owns 51,300 shares of the biopharmaceutical company’s stock valued at $3,161,000 after buying an additional 19,000 shares during the last quarter.

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.